Sumitomo Mitsui Trust Group Inc. Sells 19,128 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Sumitomo Mitsui Trust Group reduced its Bristol Myers Squibb stake by 19,128 shares, or 0.4%, leaving it with 5.07 million shares valued at approximately $316.6 million. Institutional investors and hedge funds own 76.41% of BMY.
• Bristol Myers Squibb reported stronger-than-expected quarterly results, with adjusted EPS of $1.35 versus the $1.10 consensus and revenue of $13.07 billion, up 6.9% year over year.
• The company declared a quarterly dividend of $0.63 per share, representing a $2.52 annualized payout and a 4.0% yield. Analysts remain mixed, with an average “Hold” rating and a consensus price target of $65.46.

Sumitomo Mitsui Trust Group Inc. decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,072,993 shares of the biopharmaceutical company's stock after selling 19,128 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.25% of Bristol Myers Squibb worth $316,555,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at about $27,000. Addison Advisors LLC bought a new position in Bristol Myers Squibb in the 2nd quarter valued at about $32,000. Groupe la Francaise grew its position in Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 501 shares in the last quarter. Arlington Trust Co LLC bought a new position in Bristol Myers Squibb in the 2nd quarter valued at about $35,000. Finally, Kilter Group LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at about $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 1.7%

BMY opened at $62.46 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company has a market capitalization of $127.59 billion, a PE ratio of 13.85, a P/E/G ratio of 0.33 and a beta of 0.19. The stock's fifty day moving average is $62.80 and its 200-day moving average is $59.94. Bristol Myers Squibb Company has a one year low of $45.20 and a one year high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 62.78% and a net margin of 18.47%. The business had revenue of $13.07 billion during the quarter, compared to analysts' expectations of $12.72 billion. During the same quarter last year, the business posted $1.63 earnings per share. The company's quarterly revenue was up 6.9% on a year-over-year basis. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.40 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb's payout ratio is 55.88%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on BMY. Citigroup restated a "neutral" rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Guggenheim reaffirmed a "buy" rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. TD Cowen began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "buy" rating for the company. Argus upgraded shares of Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price objective for the company in a report on Wednesday, August 5th. Finally, Royal Bank Of Canada reiterated a "sector perform" rating on shares of Bristol Myers Squibb in a research note on Monday, October 19th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $65.46.

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.